PharmacoEconomics

The Generalisability of Pharmacoeconomic Studies: Issues and Challenges Ahead
pp. 937-945(9)
Authors: Mason, James M.; Mason, Anne R.

QALYs: Are They Helpful to Decision Makers?
pp. 947-952(6)
Authors: McGregor, Maurice; Caro, J. Jaime

Should We Abandon QALYs as a Resource Allocation Tool?
pp. 953-954(2)
Author: Vijan, Sandeep

Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting: A Pharmacoeconomic Review
pp. 955-970(16)
Author: Lachaine, Jean

Single-Inhaler Combination Therapy for Asthma: A Review of Cost Effectiveness
pp. 971-988(18)
Authors: Akazawa, Manabu; Stempel, David A.

Disability and Quality of Life in Post-Traumatic Stress Disorder: Impact of Drug Treatment
pp. 989-998(10)
Authors: Seedat, Soraya; Lochner, Christine; Vythilingum, Bavanisha; Stein, Dan J.

Hospitalisation Costs of Cystic Fibrosis
pp. 999-1009(11)
Authors: Schreyögg, Jonas; Hollmeyer, Helge; Bluemel, Miriam; Staab, Doris; Busse, Reinhard

The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis
pp. 1011-1020(10)
Authors: Welsing, Paco M.J.; Severens, Johan L.; Hartman, Margriet; van Gestel, Anke M.; van Riel, Piet L.C.M.; Laan, Roland F.J.M.

The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US
pp. 1021-1033(13)
Authors: Sullivan, Patrick W.; Arant, Thomas W.; Ellis, Samuel L.; Ulrich, Heather

Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?
pp. 1035-1038(4)
Authors: Shantsila, Eduard; Watson, Timothy; Lip, Gregory Y.H.